Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Inks Agreements with Mount Sinai, CHOP Around Ingenuity Variant Analysis

Premium

Qiagen said this week that the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai School of Medicine has selected its Ingenuity Variant Analysis software solution for translational research applications around characterizing and identifying rare diseases.

In addition, the software will also be used for training purposes. Research scientists and medical students at the institute will also use Variant Analysis to analyze data from their own genomes.

Qiagen also announced that the Center for Applied Genomics at the Children's Hospital of Philadelphia has integrated Variant Analysis into a bioinformatics pipeline that it is using for a next-generation sequencing-based study that aims to identify causative variants in rare pediatric diseases.

The financial details of both agreements were not disclosed.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.